Cost-effectiveness of stent-retriever thrombectomy in large vessel occlusion strokes of the anterior circulation: Analysis from the French societal perspective

ObjectivesTo determine the cost-effectiveness of stent retriever thrombectomy (SRT) added to standard of care (SOC) in large vessel occlusion (LVO) strokes, adopting the French societal perspective given the lack of published studies with such perspective.MethodsWe developed an hybrid model (decision tree until one year post-stroke followed by a Markov model from one year onward). The time horizon was 20 years. We calculated transition probabilities across the modified Rankin Scale (mRS) based on a published meta-analysis. The main outcome measure was quality adjusted life-years (QALYs) gained. Resources and input costs were derived from a literature search. We calculated the incremental cost-effectiveness ratio (ICER) expressed as cost/QALY. We used 1-way deterministic and probabilistic sensitivity analysis (PSA) to evaluate the model uncertainty.ResultsIn the base-case, adding SRT to SOC resulted in increased effectiveness of 0.73 QALY while total costs were reduced by 3,874€ (ICER of −5,400€/QALY). In the scenario analysis adopting the French healthcare system perspective, the ICER was 4,901€/QALY. Parameters the most influential were the relative risks of SRT over SOC for 90-days mortality and for 90-days mRS 0–2, and the time horizon. PSA showed the 95% confidence interval of the ICER was −21,324 to 4,591€/QALY, with SRT having 85.5% chance to be dominant and 100% to be cost-effective at a threshold of 50,000€/QALY.ConclusionSRT was dominant from a French societal perspective, from 9 years post-stroke onwards. Cost-effectiveness of SRT added to SOC becomes undisputable with evidences from payer and societal viewpoints.     

The low-profile Neuroform Atlas stent in the treatment of wide-necked intracranial aneurysms – immediate and midterm results: An Italian multicenter registry

Background and purposeWide-necked brain aneurysms therapy remains a challenge for neurointerventionalists, mainly for the high recurrence rate. Low-profile stents make feasible the treatment of these aneurysms. In our multicenter series we analyzed clinical and angiographic results of Neuroform Atlas stent-assisted coiling.Materials and methodsFrom January 2016 to March 2017, 113 wide-necked aneurysms were discovered with CTA, MRA and DSA. The Atlas stent-assisted coiling procedures were performed under general anesthesia with sequential or jailing techniques. Six months follow-up DSA was performed to assess the recurrence rate through the modified Raymond-Roy occlusion scale (RROC). Moreover, patients were evaluated clinically to analyse the degree of disability according to the mRS. MRI was performed at 12 months evaluating both the cerebral tissue and the vessels.ResultsIn all the procedures it was feasible to navigate the Neuroform Atlas to the goal vessel and deploy the stent across the aneurysmal neck. Intra-procedural complications account for the 6.2% (7/113). The immediate occlusion rate was RROC 1 in 88%, 2 in 9% and 3 in 3% of cases. The 6 months clinical data showed mRS Score 0–1 in 96.5% of patients; 3 patients died of complications related to SAH. The 12 months follow-up showed RROC of 1 in 82%, 2 in 13% and 3 in 5% of cases. No aneurysm has been retreated.ConclusionsIn our multicenter experience the Neuroform Atlas stent assisted-coiling has shown to be a safe and effective technique for the treatment of wide-necked intracranial aneurysms with encouraging clinical and angiographic results.     

I125 irradiation stent for treatment of hepatocellular carcinoma with portal vein thrombosis: A meta-analysis

PurposeA meta-analysis aimed to systematically evaluate the safety and efficiency of I¹²⁵ irradiation stent placement for patients with hepatocellular carcinoma (HCC) combined with portal vein tumor thrombosis (PVTT).Materials and methodsThe Cochrane library, PubMed/Medline, EMBASE, CNKI, Wanfang Data and CQVIP were systematically screened out from the earliest to December 2019. The qualities of all included studies were assessed. The primary endpoints were the 6-month, 12-month stent cumulative patency rate and 6-month, 12-month, 24-month overall survival rate while the secondary endpoints were the objective response rate of PVTT, main portal venous pressure changes and treatment-related adverse events. Our meta-analysis was conducted using Stata 12.0 software.ResultsTotally seven studies with 1018 patients were included in the final analysis, in which 602 patients received TACE and I¹²⁵ irradiation stent placement, and 416 patients in control group underwent TACE and stent placement without endovascular brachytherapy (EVBT). Meta-analysis showed that the I¹²⁵ irradiation stent improved the cumulative stent patency rates in 6 months [OR = 1.65, 95% CI (1.32–2.05), P < 0.001] and 12 months [OR = 2.55, 95% CI (1.90–3.42), P < 0.001] and the survival rates in 6 months [OR = 1.77, 95% CI (1.41–2.22), P < 0.001], 12 months [OR = 3.14, 95% CI (2.24–4.40), P < 0.001] and 24 months [OR = 7.39, 95% CI (3.55–15.41), P < 0.001]. However, there was no difference in the objective response rate of PVTT [OR = 1.13, 95% CI (0.87–1.48), P = 0.365], main portal venous pressure and the occurrence adverse event [OR = 0.88, CI = 0.72–1.08, P = 0.212] between two groups.ConclusionI¹²⁵ irradiation stent seems to be more effective in treating hepatocellular carcinoma with portal vein tumor thrombosis. The usage of portal vein stent combined endovascular brachytherapy has the potential to act as an alternative therapy for HCC with PVTT. On account of the limitation of studies included, more studies with high-level evidence, such as RCTs, are requisite to support the above promising results.     

Safety and efficacy of the Yukon Choice Flex sirolimus-eluting coronary stent in an all-comers population cohort

Aims

The use of biodegradable-polymer drug-eluting stents has been shown to provide favorable results when compared with durable polymer drug-eluting stents and long-term follow up data have recently shown significant reductions in terms of very late stent thrombosis.Aim of the present study was to assess the safety and efficacy profile of a novel biodegradable polymer DES, the Yukon Choice Flex sirolimus-eluting stent.

Methods

We report here the one-year clinical outcomes associated with the use of the Yukon Choice Flex sirolimus-eluting stent in an all-comers patient population. The present stent represents a further refinement of the stent platform tested in the ISAR TEST 3 and 4 randomized clinical trials. A total of 778 consecutive patients undergoing implantation of this stent were enrolled in the present observational study and prospectively followed for one year.

Results

The use of the Yukon Choice Flex stent in a patient population with complex coronary lesion morphology was associated with optimal immediate angiographic results. At one year follow up the rates of death, myocardial infarction, definite stent thrombosis and ischemia-driven target lesion revascularization were respectively 2.4%, 1.9%, 0.3% and 11.3%.

Conclusions

The use of the sirolimus-eluting biodegradable polymer Yukon Choice Flex stent in an all-comers population of patients with complex coronary artery disease is associated with a favorable safety and efficacy profile up to one year follow up.     

多支架植入治疗恶性高位梗阻性黄疸

目的:评价高位恶性梗阻性黄疸多支架治疗的疗效及临床价值。材料与方法:26例高位恶性梗阻性黄疸。经单侧穿刺放置2枚支架18例,双侧穿刺放置支架8例,其中5例放置2枚支架,3例放置3枚支架,共植入支架51枚。结果:所有病例均一次完成支架植入,技术成功率100%。治疗后总胆红素由318.5±67.7μmol/L降至142.6±49.3μmol/L,无严重并发症发生。结论:多支架植入有利于提高高位恶性梗阻性黄疸的减黄效果,有利于进一步提高病人的生存质量和延长生存期。     

经桡动脉冠状动脉介入治疗老年冠心病患者的临床观察

目的:评价经桡动脉行冠状动脉介入(PCI)治疗老年冠心病患者的临床疗效及安全性。方法:选择256例老年(年龄≥70岁)冠心病患者,分为桡动脉组(164例)和股动脉组(92例),比较2组临床基线、PCI成功率、造影剂用量、手术时间及并发症的发生率。结果:桡动脉组手术成功率为98.2%。股动脉组手术成功率为98.9%,2组手术时间和造影剂用量比较,差异无统计学意义,桡动脉组4例出现血管并发症,股动脉组9例出现并发症,2组比较有统计学意义,桡动脉组和股动脉组患者术后6个月时严重心脏不良事件发生率比较,差异无统计学意义。结论:经桡动脉冠状动脉介入治疗老年冠心病患者是安全有效的治疗方法。     

应变率成像评价冠心病患者支架置入术后局部心肌功能的临床价值

目的 探讨应变率成像(SRI)技术评价冠心病患者冠状动脉支架置入术后局部心肌功能的临床价值.方法 应用应变率成像技术测定28例冠心病患者冠状动脉支架置入术前、术后(20±5)d及20例正常人左室壁各节段收缩期、收缩期后及舒张早期的纵向峰值应变率SRS、SRPSS、SRE,计算收缩期后收缩波(PSS)发生率及SRPSS/SRS比值.结果 与正常对照组相比,冠心病组缺血节段的SRS和SRE显著降低(P<0.01),PSS发生率,SRPSS和SRPSS/SRS显著增高(P<0.05).冠心病组缺血节段支架置入术前、术后PSS发生率,SRPSS、SRS和SRE的改变均无统计学意义(P>0.05),而SRPSS/SRS术后较术前显著减低(JP<0.01).结论 SRPSS/SRS比SRS、SRE、SRPSS更能敏感地评价支架置入术后局部心肌功能改善状况.     

Budd-Chiari综合征合并下腔静脉长节段血栓及上消化道出血的介入治疗

目的探讨Budd-Chiari综合征(BCS)合并下腔静脉长节段血栓及上消化道出血的介入治疗方法,评价下腔静脉多支架顺序置入固定血栓+下腔静脉成形术+肝静脉成形术的治疗价值。资料与方法搜集2009年1月至2011年3月6例BCS合并下腔静脉长节段血栓及上消化道出血患者。上消化道出血控制稳定1周后,均以如下介入方法治疗:下腔静脉多支架顺序置入固定血栓+下腔静脉成形术+必要时肝静脉成形术。术后予以抗凝并随访。结果 6例患者以下腔静脉多支架顺序置入压迫血栓+下腔静脉成形术+必要时肝静脉成形术治疗,均获成功。近中期临床疗效明显。主要并发症为无症状性肺栓塞,共2例。无手术致死病例。结论下腔静脉多支架顺序置入固定血栓+下腔静脉成形术+肝静脉成形术,对治疗BCS合并下腔静脉长节段血栓及上消化道出血是安全、有效的,可以作为BCS伴下腔静脉长节段血栓及上消化道出血的治疗选择。     

解剖M型技术评价PTCA及支架置入术后左室室壁运动

目的应用解剖M型超声心动图(AMM)评价经皮腔内冠状动脉成形术(PTCA)及支架置入术前后左室室壁运动的改变。方法全组45例,为进行冠状动脉左前降支(Left anterior descending,LAD)PTCA及支架植入的患者,在术前72h、术后72h及3个月时分别进行超声心动图检查,AMM测量左室短轴基底段(二尖瓣水平)和中段(乳头肌水平)前间隔、前壁的收缩期增厚率及室壁运动幅度。结果45例患者术后72 h及3个月检查显示,LAD对应节段(前壁和前间隔)的收缩期增厚率及室壁运动幅度均较术前显著增高(P<0.05,P<0.01)。结论PTCA及支架置入术能迅速改善狭窄冠状动脉供血区域的室壁运动。采用AMM测量对应室壁节段的收缩期增厚率及室壁运动幅度能准确评价PTCA及支架置入术的疗效。